DexCom, Inc. filed a Form 8-K on October 29, 2026, disclosing a Board-authorized share repurchase program of up to $1.0 billion and announcing financial results for the quarter ended September 30, 2026.

Key Highlights

  • $1.0 billion repurchase authorization: DexCom's Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of outstanding common stock.
  • Program end date: The repurchase period is set to end no later than December 31, 2027, according to the filing.
  • Par value: The common stock subject to repurchase carries a par value of $0.001 per share.
  • Repurchase methods: Purchases may be made in the open market, in privately negotiated transactions, or through other methods, including Rule 10b5-1 trading plans.
  • No obligation to repurchase: The filing states the program "does not obligate Dexcom to repurchase any dollar amount or number of shares," and may be extended, modified, suspended, or discontinued at any time.
  • Q3 2026 results announced: A press release covering financial results for the quarter ended September 30, 2026, was furnished as Exhibit 99.1 to the filing.

DexCom Discloses $1.0 Billion Buyback Authorization and Q3 2026 Results Filing

DexCom, Inc. (NASDAQ:DXCM) disclosed in an October 29, 2026 Form 8-K that its Board of Directors had authorized and approved a share repurchase program of up to $1.0 billion of the company's outstanding common stock, par value $0.001 per share. According to the filing, the repurchase period runs through no later than December 31, 2027.

The filing details that repurchases under the program may be executed through multiple channels, including open market purchases, privately negotiated transactions, and trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The company disclosed that all repurchases must comply with limitations set forth in Rule 10b-18 and other applicable federal and state laws and regulations. The filing notes that the timing of any repurchases "will depend on market conditions and will be made at Dexcom's discretion."

The company also disclosed, under Item 2.02, that it issued a press release on October 29, 2026, announcing financial results for the quarter ended September 30, 2026. That press release was furnished as Exhibit 99.1 and is noted as "furnished" rather than "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. The filing was signed by Jereme Sylvain, Executive Vice President, Chief Operating Officer and Chief Financial Officer, designated as Principal Financial and Accounting Officer.

What Was Disclosed

DexCom filed an 8-K on October 29, 2026, reporting a Board-approved share repurchase program of up to $1.0 billion expiring no later than December 31, 2027, and furnishing a press release with third-quarter 2026 financial results.